An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease-Reference-Cited by-同舟云学术

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease

Published:2017-07-20 Issue:3 Volume:130 Page:360-367
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Martin Paul J.¹²^ORCID,Storer Barry E.¹,Inamoto Yoshihiro¹,Flowers Mary E. D.¹²,Carpenter Paul A.¹³,Pidala Joseph⁴,Palmer Jeanne⁵,Arora Mukta⁶,Jagasia Madan⁷,Arai Sally⁸,Cutler Corey S.⁹,Lee Stephanie J.¹²

Affiliation:

1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Department of Medicine and

3. Department of Pediatrics, University of Washington, Seattle, WA;

4. Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL;

5. Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ;

6. Department of Medicine, University of Minnesota, Minneapolis, MN;

7. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;

8. Department of Medicine, Stanford University Medical Center, Stanford, CA; and

9. Department of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Abstract

Key Points Complete or partial response at 1 year without secondary systemic treatment provides clinical benefit in patients with chronic GVHD. Success defined by this endpoint is currently observed in fewer than 20% of patients after initial systemic treatment of chronic GVHD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/3/360/1404451/blood775767.pdf

Reference18 articles.

1. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria;Flowers;Blood,2011

2. Current issues in chronic graft-versus-host disease;Socié;Blood,2014

3. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD;Vigorito;Blood,2009

4. Characteristics of chronic GVHD after cord blood transplantation;Newell;Bone Marrow Transplant,2013

5. How I treat chronic graft-versus-host disease;Vogelsang;Blood,2001

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

2. Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort;International Journal of Hematology;2024-07-17

3. Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study;Bone Marrow Transplantation;2024-05-02

4. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies;Hematology;2023-12-08

5. Telemedicine in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T Cell Therapy;Cancers;2023-08-15